Total trials
39
Active
4
Phase 3
24
Total enrollment
8,945
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Budesonide | — | — | — | — | 12 | ||
| norUrsodeoxycholic acid | — | — | — | — | 2 | ||
| norucholic acid | — | — | — | — | — | 1 | |
| ZED1227 + SIGE | — | — | — | — | — | 1 |
Next readouts
- 2025-01
- 2026-12
- 2027-08
- 2027-09
Top conditions
- Eosinophilic Esophagitis5
- Ulcerative Colitis3
- Primary Sclerosing Cholangitis3
- Colitis, Ulcerative3
- Crohn's Disease2
- Crohn´s Disease2
- Diverticulitis2
- Primary Biliary Cirrhosis2
Frequently asked questions about Dr. Falk Pharma GmbH
- How many clinical trials does Dr. Falk Pharma GmbH have on ClinicalTrials.gov?
- Dr. Falk Pharma GmbH is listed as the lead sponsor on 39 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Dr. Falk Pharma GmbH's trials are in Phase 3?
- 24 of Dr. Falk Pharma GmbH's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Dr. Falk Pharma GmbH focus on?
- Dr. Falk Pharma GmbH's most-studied conditions on ClinicalTrials.gov are Eosinophilic Esophagitis, Ulcerative Colitis, Primary Sclerosing Cholangitis, Colitis, Ulcerative, Crohn's Disease.
- When are Dr. Falk Pharma GmbH's next clinical trial readouts?
- Dr. Falk Pharma GmbH has 4 upcoming primary-completion readouts tracked here; the soonest is “norUrsodeoxycholic Acid vs Placebo in PSC”, expected around 2025-01.